The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.
 
Jens Bedke
Consulting or Advisory Role - Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Ipsen; Janssen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Merck KGaA (Inst)
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Joan Palou
No Relationships to Disclose
 
Daniel Saltzstein
Consulting or Advisory Role - Astellas Pharma; Janssen; Pfizer Medivation
 
Félix Guerrero-Ramos
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Combat Medical; Janssen; Johnson & Johnson/Janssen; Merck; MSD Oncology; Nucleix; Palex; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Janssen Oncology; Johnson & Johnson/Janssen; Merck; Nucleix; Pfizer; Roche
Speakers' Bureau - AstraZeneca; BMS GmbH & Co. KG; Combat Medical; Janssen Oncology; Nucleix; Palex; Pfizer
Research Funding - Combat Medical; Roche
Patents, Royalties, Other Intellectual Property - BlaDimiR, miRNA-based diagnostic urine test.
Expert Testimony - Johnson & Johnson/Janssen; Nucleix
Travel, Accommodations, Expenses - AstraZeneca; Combat Medical; Fidia Farmaceutici S. p. A.; Ipsen; Italfarmaco; Janssen Oncology; Johnson & Johnson/Janssen; Nucleix; Pfizer; Recordati; SALVAT
 
Motonobu Nakamura
No Relationships to Disclose
 
Tilman Todenhoefer
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/Merck; Bayer; Bristol-Myers Squibb/Sanofi; Janssen; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche; Sanofi/Aventis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Basilea (Inst); Bayer (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); RhoVac (Inst)
 
Raj Satkunasivam
Consulting or Advisory Role - Pfizer
Research Funding - Anchiano (Inst); BMS GmbH & Co. KG (Inst); CG Pharmaceuticals (Inst); CoImmune (Inst); enGene (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Photocure (Inst); Protara Therapeutics (Inst); QED Therapeutics (Inst); UroGen pharma (Inst)
 
Peter Black
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Combat Medical; EMD Serono; Ferring; Janssen Oncology; Merck; Nanobot; Nanobot; NanOlogy; Nonagen Bioscience; Pfizer; Photocure; Prokarium; Sumitomo Pharma Oncology; TerSera; Tolmar; Verity Pharmaceuticals
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer; TerSera
Patents, Royalties, Other Intellectual Property - 1. PCT/CA2014/000787. Canada. 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.
 
Julia Brinkmann
Employment - Guerbet (I); Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jane Chang
Employment - Pfizer
Stock and Other Ownership Interests - Bayer; BMS; Pfizer; Viatris
Research Funding - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Anthony Eccleston
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Arlene Reisman
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jennifer Vermette
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Gary Steinberg
Stock and Other Ownership Interests - CG Oncology; enGene; Epivax Therapeutics
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Aura Biosciences; Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals